Table 2.

League table showing pooled risk ratios for primary and secondary endpoints.

Endpoint	Placebo	SGLT2i	Vericiguat	Omecamtiv Mecarbil
CV death or HF hospitalization
	Placebo	0.77 (0.71–0.83)	0.92 (0.85–0.99)	0.96 (0.91–1.02)
	1.30 (1.20–1.41)	SGLT2i	1.19 (1.07–1.33)	1.25 (1.13–1.39)
	1.09 (1.01–1.17)	0.84 (0.75–0.93)	Vericiguat	1.05 (0.96–1.15)
	1.04 (0.98–1.10)	0.80 (0.72–0.88)	0.95 (0.87–1.04)	Omecamtiv mecarbil
CV death
	Placebo	0.85 (0.75–0.96)	0.94 (0.83–1.06)	1.01 (0.93–1.10)
	1.18 (1.04–1.33)	SGLT2i	1.10 (0.93–1.31)	1.19 (1.03–1.38)
	1.07 (0.95–1.21)	0.91 (0.76–1.08)	Vericiguat	1.08 (0.93–1.25)
	0.99 (0.91–1.08)	0.84 (0.72–0.98)	0.93 (0.80–1.08)	Omecamtiv mecarbil
All-cause death
	Placebo	0.86 (0.77–0.95)	0.96 (0.86–1.07)	1.00 (0.93–1.07)
	1.16 (1.05–1.29)	SGLT2i	1.11 (0.96–1.29)	1.16 (1.02–1.32)
	1.05 (0.94–1.16)	0.90 (0.77–1.04)	Vericiguat	1.04 (0.92–1.19)
	1.00 (0.93–1.08)	0.86 (0.76–0.98)	0.96 (0.84–1.09)	Omecamtiv mecarbil
HF hospitalization
	Placebo	0.73 (0.66–0.81)	0.92 (0.84–1.00)	0.97 (0.90–1.04)
	1.37 (1.24–1.52)	SGLT2i	1.26 (1.10–1.44)	1.33 (1.17–1.50)
	1.09 (1.00–1.19)	0.79 (0.69–0.91)	Vericiguat	1.05 (0.94–1.18)
	1.03 (0.97–1.11)	0.75 (0.67–0.85)	0.95 (0.85–1.06)	Omecamtiv mecarbil

Values are reported as pooled risk ratios and 95% confidence intervals. The pooled effect estimates obtained from the network meta-analysis are reported for column intervention relative to raw. CV—cardiovascular; HF—heart failure; SGLT2i—sodium-glucose cotransporter 2 inhibitors.